In this review blood component therapy for acute haemorrhage is summarised. As the haemotherapy is frequently the cornerstone of a successful outcome of haemorrhagic shock, attention to details in relation to the indications, safety and efficiency is essential. Massive blood transfusion brings with it many potential complications which may jeopardise a successful outcome for the patient after skilful medical and surgical care has controlled the basic problem.
Few would argue that homologous blood transfusion is the greatest single advance in the management of haemorrhagic shock. There have been various milestones in the introduction of blood transfusion into clinical medicine. Early attempts were thwarted by serological incompatibility leading on occasions to disastrous outcomes. With Karl Landstainer's Nobel Prize-winning discovery in 1900 of the ABO blood group system, it became possible to give compatible blood to more than 99070 of recipients. The subsequent anticoagulation, preservation and storage of blood led to the development of blood banks, and the ready availability of blood for acute haemorrhage.
As with much technological progress, many of the major advances in clinical blood transfusion have been precipitated by war. Most advances in blood preservation and fractionation resulted from research done during the Second World War, and the Korean and Vietnam conflicts. The fractionation of blood into its various components is now a highly sophisticated science. Some clinical blood transfusionists advocate that all haemotherapy should be given as blood component therapy, and that there are virtually no indications for the use of whole blood. This is not my view, and the aim in this review will be to consider an overall approach to haemotherapy for acute haemorrhage.
The availability of blood and its components has not only led to the survival of many patients suffering acute haemorrhage, but it has also permitted more complex surgery to be performed. It cannot be over-emphasised that the total management of the acutely bleeding patient must be a co-ordinated and multidisciplinary effort. There should be a priorityoriented management of the problem as outlined by Drs. More and Fisher in this symposium. The clinical blood transfusionist and laboratory technologist have important roles in supplying the required products as rapidly and safely as possible. In complex clinical settings where established shock has occurred, or acute haemorrhage cannot be controlled, the clinical blood transfusionist may have an important role in advising on aspects of haemotherapy and in the assessment of complications of massive blood transfusion.
ELECTIVE VERSUS ACUTE UNEXPECTED HAEMORRHAGE Adequate preparations for the possible occurrence of massive blood loss in an elective situation should be emphasised. Any patient admitted to hospital or likely to undergo major surgery should be adequately assessed from the haematological and blood transfusion point of view. Pre-operative haematological assessment is not the subject of this review, but let it be emphasised that any pre-existing defects in oxygen transport, haemostatic system or host defences should be clearly identified and appropriate measures taken to correct the abnormality, if possible. It is possible to perform major surgery on patients with defects in the haemostatic system, as long as that defect has been clearly identified and the appropriate blood component administered. When sudden haemorrhage occurs in relation to elective surgery, the supply of blood is facilitated as the patient's ABO and Rh blood group is known, the serum has been studied for atypical antibodies, and blood is probably immediately available (Table 1) . Haemotherapy can be instituted rapidly, and established haemorrhagic shock should not occur. This is in contrast to haemorrhage occurring unexpectedly when the patient is not immediately resuscitated. In this situation not only may established hypovolaemic shock be present, but the supply of compatible blood will take longer as the blood bank does not usually have any previous knowledge of the patient.
SEROLOGICAL CONSIDERATIONS
Attention to the administration of ABOcompatible blood remains the single most important factor in the safety of blood transfusions. Most acute haemolytic transfusion reactions due to ABO incompatibility are the result of clerical errors at some point in the blood supply chain. Correct identification of the patient at every link in the blood supply chain is ,paramount. The most precarious link remains identification of the patient and blood sample at the time of collection. If a blood sample is incorrectly identified at this point, the error will be perpetuated along the line. Unless the patient has been previously blood-grouped by the transfusion service' in question, the error will not be detected. Further, Table 2 outlines the probability of a transfusion being compatible with the recipient, in relation to the ABO grouping, Rh grouping and crossmatch status of the donor blood. The major point highlighted in this table is the fact that the quantum leap in compatibility of blood occurs when ABO compatibility is ensured. The further grouping and crossmatching procedures do little to increase the probability of a transfusion being safe. This is not to underemphasise the role of Rh grouping and crossmatching. When a patient has been transiused previously the chance of there being an atypical antibody is greater, and the probabilities in this table will clearly be altered. If a blood group and antibody screen has been performed on a patient, blood can be administered remarkably safely in an urgent situation, although the crossmatch may not be completed. However, as a general rule, because of the importance of ABO blood group compatibility, it is wise that blood should not be administered until the saline crossmatch result is available. A saline crossmatch is a rapid procedure and can be performed by most blood banks in five to ten minutes. The Al1aeslhesia and Intensive Care, Vol. 12, No. 3, AUgllSI, 1984 advantage of having the saline crossmatch result available is the virtual guarantee of ABO compatibility. The latter phases of the crossmatch (Coombs Test, enzyme method, albumin methods) are for detecting incomplete antibodies, particularly of the Rh system. If the antibody screen is clear, the chance of an atypical antibody being detected on the crossmatch is remarkably small. 1 Sudden haemorrhage in an elective situation, where the patient has had a blood group and antibody screen performed, allows the blood bank to provide saline-compatible groupspecific blood in the majority of patients within five to ten minutes. In the urgent unexpected haemorrhage the safety margin will not be as great. In the exsanguinated patient who is likely to die, the most appropriate therapy is group 0, Rh negative, low anti-A and anti-B haemolysin blood. 2 Such blood is not commonly (immediately) available in large amounts. The use of packed cells reconstituted with colloid or crystalloid will help circumvent the uncommon problem of high titre ABO haemolysins. If Rh positive blood is the only blood available, it should not be withheld if the patient is likely to die. If the blood group is not known the probability of the patient being Rh positive is 85070, and in the Rh negative patients, it is unlikely that they will have an anti-D antibody in any case.
It is rarely necessary to give group 0 uncrossmatched blood. In most cases there is adequate time, while volume resuscitation with clear fluids is occurring, to perform a group and saline crossmatch. It should be emphasised that the patient's group should be determined at the time, and no previous information in relation to blood groups should automatically be accepted. There have been occasions where the clinician has assumed he is giving groupspecific blood on the basis of information obtained from the patient, or from the patient's notes, which later turned out to be incorrect.
WHOLE BLOOD VERSUS BLOOD COMPONENTS
With increasing expertise in the fractionation of blood into its various components, there has been pressure placed on clinicians to use only blood components, and avoid whole blood. This has led to protracted and frequently heated debate. Some blood banks insist that Anaesthesia and intensive Care, Vo!. 12, No, 3, Augllsl, 1984 100070 fractionation of all donated blood should occur, whereas others believe that 70070 to 80070 fractionation is desirable.
It has become clear in recent years that storing blood in its unaltered state for long periods of time is undesirable. This not only leads to progressive deterioration in red cell survival, but to accumulation of microaggregates, alteration to the plasma, and loss of platelets occurS. 3 -6 Survival of most of the components is improved when they are separated. There is thus a good argument for fractionating all blood which is not likely to be transfused within a week of collection. The acutely haemorrhaging patient who continues to bleed, or has established shock, is likely to require many of the components of blood including red cells, plasma proteins, and platelets. These will best be supplied, with exposure to the least number of donors, by the use of whole blood that is relatively fresh. However, it is not possible to have fresh whole blood available for all emergencies. It is also illogical to crossmatch large amounts of whole blood for elective surgery when it is unlikely to be transfused.
In most elective situations, red cell concentrates are quite adequate for initial resuscitation. Volume can be provided with the use of plasma protein solutions or fresh frozen plasma. Many clinicians have not appreciated the major Catch-22 of blood transfusion where large amounts of blood are crossmatched for elective surgery and not transfused. This ageing of the blood, of necessity, means that when transfusion is ultimately required for a patient, the blood is likely to have been stored for a considerable period of time. It is thus not logistically possible to give fresh blood only to those patients who bleed and to keep stored blood for those patients who do not bleed. This will clearly lead to outdating and wastage of blood.
The introduction of the group and screening system for elective surgery has been an attempt to reduce this unnecessary dating of blood. By achieving this, it is likely that fresher blood will be available for patients who actually require transfusion. The specific advantages of the use of fresh blood less than one week old, and ultra-fresh blood (non-refrigerated blood), will be discussed below.
In general most acutely bleeding patients can initially be managed with the use of packed cells and volume expanders. In the early stages of haemorrhage, unless there is a pre-existing defect, or an acutely acquired defect, plasma coagulation proteins and platelets are not needed. It is only after continuing haemorrhage, with the development of dilution and other complications, that closer attention must be given to platelet and plasma protein deficiencies.
LOGISTIC AND PRIORITY ASSESSMENT IN MASSIVE BLOOD TRANSFUSION
A massive blood transfusion is usually defined as total replacement of the patient's circulating blood volume within a few hours. This situation is much more common these days in both the acute trauma setting and also in elective surgery. As a result of advances in resuscitation techniques and more skilful recognition and treatment of specific problems, patients survive today who otherwise would have died. The availability of blood has been one of the most significant factors in altering the prognosis of patients with acute haemorrhage. However, the collection, storage and compatibility testing and supply of blood and blood products for the treatment of acute haemorrhage is frequently taken for granted and haemotherapy tends to be regarded as relatively simple and logical, with the blood transfusion service providing the blood products as requested. At times, there is a rather naive view that blood banks are awaiting haemorrhagic disasters with large stockpiles of blood available.
In the first instance, the top priority in resuscitation is restoration of circulating blood volume and maintenance of oxygen-carrying capacity. If haemorrhage continues, increasing attention must be directed towards the haemostatic components of the blood (platelets and coagulation factors). Although these priorities may seem obvious, there may be considerable problems in logistics surrounding haemotherapy for acute haemorrhage. Not only may there be problems in providing immediately effective red cells, platelets and coagulation factors, but there are significant complications which may result from rapid infusion of stored blood and its components. Despite all modern facilities available in large hospitals, effective resuscitation remains the most important component of management for the trauma patient. Unless a patient is rapidly and well resuscitated and the effects of massive stored blood transfusion minimised, the longterm outcome for these patients will not be improved. It is tempting to have a protocol approach to acute haemorrhage. Although in general this has some advantages, the patients have different problems requiring varying approaches to therapy.
When blood loss occurs in a controlled situation with immediate replacement and hypovolaemic shock has not occurred, a protocol approach has advantages. In a patient who is haematologically normal before the onset of haemorrhage, the loss of 20070 of blood volume can be replaced with plasma substitutes. This will usually result in a 20070 fall in the haematocrit. The next 30070 loss can usually be replaced with a combination of packed cells and plasma substitute. If bleeding proceeds beyond half the total blood volume, whole blood is usually the best form of haemotherapy. However, some workers feel that component therapy using packed cells, platelet concentrates and plasma should be used. This is not a completely acceptable approach as the recipient will be exposed to a much greater number of individual donor units than when whole blood is used. When approaching a total blood volume replacement in a short period of time, immediately functioning blood components are desirable, and reducing the complication rate to a minimum is important. The patient who continues to bleed is probably a candidate for relatively fresh blood. If possible whole blood which is less than ten days old should be used in this situation.
There should be regular monitoring of the haemoglobin, platelet count and coagulation profile to ensure that no specific defects are developing. Most clinical blood transfusionists would agree that blood loss beyond a total blood volume should have immediately functioning red cells and haemostatic factors. It should be emphasised that following massive blood transfusion the patient has foreign homologous blood circulating. As a result there may be adverse short-term and long-term consequences. Following massive blood transfusion the patient's circulating blood has, initially at least, the biochemical and physiochemical characteristics of stored blood rather than the patient's own blood. These defects are proportional to the shelf-life of the blood transfused, the volume infused and the rate of transfusion. Every effort must be made to establish surgical haemostasis as quickly as possible and minimise the need for transfusion of stored blood. The longer it takes to control the bleeding, the more likely are the problems discussed below to occur. If massive blood transfusion is anticipated or surgical haemostasis cannot be rapidly obtained the blood bank should be kept informed of the clinical situation so that optimal haemotherapy can be provided. The standard blood bank inventory control dictates that blood closest to expiry be issued first. Such a policy is acceptable for elective transfusions and small volume transfusions: however, in the case of the exsanguinated patient who has had large volumes transfused, such an approach is probably not acceptable.
THE ROLE OF UL TRAFRESH BLOOD
The term "fresh blood" should strictly apply to blood that has only just been collected, but blood bankers have extended the term to include blood that is up to a week old. The most optimistic "blood preservationists" would imply that blood 35 days old is as good as fresh, from the red cell function point of view. It is best to consider the age of blood in the following terms: Ultrafresh blood: Blood within 4 hours of collection which preferably has not been refrigerated. Fresh blood: Blood stored less than 7 days. Stored blood: Blood stored more than 7 days.
Ultrafresh blood will have all components functioning normally, fresh blood will have red cells which will transport and deliver oxygen normally immediately after transfusion, whereas stored blood will need varying periods of time (hours) for the red cells to achieve their normal function.
Depending on the local circumstances, serious consideration should be given to obtaining ultrafresh blood when more than a patient's blood volume has been replaced in less than four hours. The use of fresh blood should not negate the necessity to correctly identify any haemostatic defects which may require specific component correction. Ultrafresh blood is usually the most readily available source of all blood "components" required in the patient bleeding massively. Of necessity, blood collection on site from a donor panel or There are numerous potential complications which may ensue from the rapid massive transfusion of homologous blood (Table 3) . Transfusion must always be borne in mind as a possible cause of unexpected complications during the clinical course of a patient with reactions manifesting in numerous ways ( Table  4 ). Many of these presentations may be misinterpreted and attributed to other mechanisms. Unless the complication is temporally related closely to the infusion of the blood or components, the causal association is less likely to be realised. Table 4 lists potential clinical complications in which blood transfusion should be considered as a possible aetiological factor. In many of these clinical settings there may be several possibilities to be considered either alone or interacting with each other. For example, the generalised effects of shock are likely to have major effects on all body functions, including respiratory, cardiac, hepatic and renal. Blood, like any biological fluid, degenerates with time during storage. Qualitative and quantitative changes occur in both the cellular and plasma components, but attention in this section will be confined to the red cell. Table 5 summarises the changes which occur in blood with storage. Changes in blood due to storage Effects of additives, e.g. citrate, sodium, adenine. Accumulation of toxic products, e.g. potasssium, hydrogren ions, lactic acid, ammonium ions. Quantitative deficiency, i.e. post-transfusion survival.
TABLE4

The presentations of transfusion reactions
Qualitative defects -cellular and plasma components. Degenerative changes, e.g. microaggregates, vasoactive substances, procoagulant activity, enzymes.
The effects on red cell and haemoglobin function and their implications for oxygen transport
The red cell is dependent on the anaerobic glycolytic pathway leading to the formation of adenosine triphosphate (A TP). A TP is a central determinant of red cell viability and function, being essential to preserve the activity of the membrane, sodium-potassium pump and glucose phosphorylation and thus the red cell shape and fluidity. During preservation and storage these metabolic cycles, albeit at a slower rate, must continue in vitro if viability and post-transfusion function are to be maintained. As the A TP becomes depleted on storage and pH rises, membrane damage occurs with spherocyte formation and swelling, ultimately resulting in potassium leak. 6 . 9 Parallel to these changes haemoglobin function may be altered due to falling levels of both A TP and, more significantly, 2,3 diphosphoglycerate (2,3 DPG) resulting in increasing oxygen affinity. 10 Stored red cells undergo a progressive shape change with time from a discocyte to an echinocyte (spiky spherocytic cell) rendering the cells rigid and less capable of negotiating the microcirculation. Jl These changes occur earlier and to a greater extent in whole blood than in red cell concentrates. This difference may in part be related to the fact that varying amounts of the buffy coat may be removed during the preparation of red cell concentrates. The platelets and granulocytes removed are normally the foundations for the formation of microaggregates with various cell-damaging enzymes being released in the storage medium. As fluidity of blood is determined to a large extent by the flexibility of individual red cells, the storage effects on red cell fluidity are important but their clinical significance is only recently arousing interest. 12 The ability of stored red cells to load, unload and transfer oxygen across the capillary endothelium has been a matter of debate for several years. 8 ,ll-IS A considerable volume of literature has accumulated on the changes in 2,3 DPG levels in stored blood and their possible significance in impairing oxygen release at tissue level. [16] [17] [18] 2,3 DPG has a pronounced effect on reducing oxygen affinity of purified haemoglobin, and in the intact red cell the shift of the haemoglobin-oxygen dissociation curve with the change in 2,3 DPG is due not only to an interaction between 2,3 DPG and haemoglobin, but also to changes in intracellular pH. If stored blood depleted in 2,3 DPG and with an increased oxygen affinity is transfused, 2,3 DPG is regenerated and the oxygen affinity returns to normal within 24 hours. It is thus clear that the transfusion of large volumes of stored blood will not produce an immediate availability of oxygen to the tissues which might be anticipated by the increase achieved in haemoglobin levels.
Despite all the in vitro studies on 2,3 DPG levels in stored blood clinical relevance of reduced levels has been slow in forthcoming. 10 Techniques for studying the effects in vivo are unsatisfactory and have used models where all other links in the oxygen delivery system are intact. In the clinical setting the large number of variables operating present insurmountable problems preventing the isolation of 2,3 DPG as a single variable. A low 2,3 DPG is likely to be clinically significant when other links in the oxygen transport chain are weakened. Concurrent anaemia, cardiac decompensation or coronary insufficiency may make alterations in red cell and haemoglobin function more relevant and a good case can be made for such patients receiving fresh blood (less than 5 days old).
From the foregoing discussion it is clear that blood is altered from the moment of its collection from the donor. The lesions of storage increase during the unit of blood's shelf-life. The extent of these changes in red cell AnaeSlhesia and IlIlensi\'e Care, Vol. 12, No. 3, August, 1984 function is determined by the liquid preservative used, container, storage time and storage conditions. The first few hours following transfusion are critical for the stored red cell. Not only are the cell's oxygentransporting mechanisms malfunctioning, but the cell is fighting for its own survival and the first 12-24 hours are probably a "do or die" situation. During this time the red cell is trying to restore metabolic processes to normal, thus re-establishing red cell fluidity and haemoglobin function. The macrophagemonocyte system, particularly in the spleen, is always on the lookout for red cells with altered membrane or fluidity characteristics.
Clinical and laboratory observations suggest that the full benefit of blood transfusion in improving oxygen transport may not be realised for several hours after transfusion. These cells are likely to have difficulty negotiating the microcirculation where the capillaries are usually of smaller diameter than the average red cell. 13 Very few studies have been carried out in order to answer these questions. In vivo investigation is difficult as so many variables obscure separation of the numerous individual factors under consideration.
There is thus an increasing number of reports addressing the problems of red cell function of stored blood and the current controversies should be resolved in the next few years. 13, 19 The recent introduction of continuous mixed venous oxygen saturation measurement offers a promising new tool for dynamically studying oxygen delivery by the blood. Many of the patients falling into the massive blood transfusion category are likely to have numerous defects in oxygen transport and any further impairment of one of the links in the oxygen transport chain is likely to be disadvantageous. Thus blood which is functional immediately following transfusion is an advantage.
Microaggregates
The accumulation of particulate material in stored blood has been recognised since the early days of blood preservation and banking, and logic would suggest that these microaggregates are likely to be detrimental when infused into the recipient. [20] [21] [22] Many workers have gone to great lengths to "prove" that this debris in blood is of no clinical significance. 23 ,24 This is a rather naive assessment of the microaggregate problem and accumulating evidence would suggest that alterations in blood which lead to microaggregate formation may have farreaching, ill-understood and poorly studied effects (Table 6) . 25, 26 Antagonists of the use of microaggregate filters have established from their research that available micro filters remove only the large debris and that the small aggregates which pass through the filter may be important. A recent study of risk factors in the development of adult respiratory distress syndrome (ARDS) suggests that blood transfusion alone is unlikely to cause ARDS until more than 20 units of blood have been transfused in 12 hours. 27 However, when combined with one or more other risk factors, the volume of blood which may contribute to ARDS becomes less.
If blood transfusion is accepted as a cause or risk factor in ARDS the question of the actual pathophysiology remains unresolved. 28 -32 The last two decades have seen the development of a broad selection of microaggregate filters but their routine use in clinical blood transfusion has lagged behind for several reasons. 23 ,33 Cost, impedance of transfusion rates and practical logistic problems have had their effect. However, questions regarding their efficacy in preventing significant clinical problems, supposedly due to the presence of microaggregates, are still unresolved. With most micro filters of pore size down to 2011, achievement of the rapid flow rates often necessary in massive transfusion is difficult, even when considerable pressure is applied. Microfilters are only a temporary solution to the problem of microaggregates, and the ultimate answer lies in the prevention of microaggregate formation.
Other methods of reducing or eliminating microaggregates from stored blood include washing red cells before transfusion and the use of frozen blood. Table 6 lists the possible clinical implications of microaggregate transfusion. This list includes many complications which are likely to be encountered in severely ill trauma patients who have received massive blood transfusion, in whom the contribution made by blood transfusion is difficult to delineate. 
Haemostatic failure
The pathophysiology of haemostatic f~ilu~e in association with massive blood transfUSIOn IS complex. 34 -37 The identification of single ~auses is commonly unsuccessful. Current eVIdence indicates that the problem is usually multifactorial and therapy in the bleeding patient must consider the haem~sta!ic syste~ as a whole. Rapid efficient reSUSCItatIOn, surgIcal haemostasis and attention to the quality of blood products infused will, reduce t~e likelihood and severity of systemIC haemostatIc failure. Prevention of haemostatic failure in this way is the essence of success rather than waiting until defects develop, at which time they have to be identified and corre~ted. However in the patient who has estabhshed haemorrhagic shock and has received massive blood transfusion, it is likely that defects in the haemostatic system will be present and should be clearly identified. There should be a combined clinical and laboratory policy on the management of generalised haemostatic failure accompanying acute haemorrhage. Further aggravation of the complications of massive Possible factors contributing to haemostatic failure following massive blood transfusion Pre-existing haemostatic defect.
Loss of coagulation factors, platelets and inhibitors.
Dilution of coagulation factors, platelets and inhibitors.
Impaired synthesis due to effects of shock on liver and bone marrow function.
Effects of trauma: Disseminated intravascular coagulation and fibrinolysis.
Effects of storage lesion: Depletion of coagulation factors and platelets, aggravation or precipitation of DIe.
Depletion of modulators of haemostasis (e.g. Antithrombin Ill, fibronectin and Protein C).
Incompatible tranfusion reaction: Die.
AnaeSlhesia and Intensive Care, Vol. 12, No. 3, August. 1984 blood transfusion can be avoided or minimised if attempts are made to identify correctable defects in the haemostatic system. Table 7 lists all the possible factors which may contribute towards haemostatic failure following mas,ive transfusion. The labile Factors V and VIII are not well preserved in stored blood beyond three to four days. 37 Platelets are aggregated and nonfunctional after a shorter period of time. 39 Some of the coagulation factors may be altered due to cooling and storage, and the accumulation of microaggregates and degenerative cells may be responsible for aggravating or initiating disseminated intravascular coagulation. 26 The relative importance of the different mechanisms outlined in Table 7 is difficult to determine. Clearly, congenital or pre-existing haemostatic defects should be borne in mind and rapidly identified. One of the commonest acquired defects seen in relation to trauma patients is probably the combination of alcohol and aspirin producing platelet dysfunction. 39 In the majority of acutely bleeding patients, dilution of the haemostatic components is probably the most important mechanism of haemostatic failure. If haematological investigation clearly identifies a specific quantitative or qualitative defect in the haemostatic system it is logical to infuse the appropriate concentrate. Under these circumstances haemorrhage is usually not controlled until the specific pathology has been identified and corrected.
In a recent prospective study of haemostatic failure in association with massive blood transfusion, only 7frlo of patients had completely normal haemostatic tests. 40 In 48frlo, a well-defined haemostatic defect such as disseminated intravascular coagulation (DIC), heparin effect or liver disease was identified. In the remaining 45 frlo, the defects were less specific with thrombocytopenia being the main abnormality. There was an inverse correlation in this latter group between the laboratory abnormalities and the number of units transfused, suggesting that abnormalities were induced by the massive transfusion. Standard protocol approaches to acute blood replacement without evaluation of haemostasis did not reduce the incidence of abnormalities nor the blood component requirements. The diagnosis and significance of DIC in trauma patients may be difficult to determine. Many of the laboratory abnormalities found in DIC are difficult to interpret in the presence of shock, trauma and oliguria. There is some evidence that blood transfusion itself may cause or contribute to DIe. As a general rule it is rare that any specific therapy, such as heparin, need be used to control DIe. All efforts should be centred towards controlling the haemorrhage and preventing established shock occurring.
Hypothermia
The maintenance of adequate body temperature during resuscitation is crucial. 41 Hypothermia impairs the metabolism of citrate and lactate, shifts the oxygen dissociation curves to the left, increases in tracellular potasslUlm release, impairs red cell deformability, delays drug metabolism, masks clinical signs, increases the incidence of arrythmias and reduces cardiac output. Hypothermia following the infusion of stored blood or other cold solutions can be eliminated as a problem if efficient blood warmers are available which are able to deliver the fluid at temperatures above 32°e.
Acid base alterations and electrolyte disturbances
The transfusion of stored blood provides a significant acid load from citric acid and lactic acid. 42 ,43 This may cause appreciable problems in a patient who already has a metabolic acidosis from shock. Under normal circumstances the routine use of alkali is usually unnecessary and generally contraindicated. Most of the acid load is rapidly buffered and the citrate metabolised with the end result being a metabolic alkalosis.
Although stored blood may have significantly elevated potassium levels in the plasma, this does not usually create a problem during resuscitation unless the patient already has hyperkalaemia or renal failure. A more likely problem is hypokalaemia which may occur hours after resuscitation as the transfused cells correct their electrolyte composi tion and potassium returns into the cells.
Citrate toxicity and hypocalcaemia
From the earliest days of blood transfusion citrate toxicity has been recognised as a problem, but its recognition and management still remain a matter of debate. 45 The body responds to excess citrate in two ways. First, metabolic removal and second, mobilisation of ionised calcium. Marked elevations in citrate will occur if transfusion exceeds 500 ml in five minutes. Unless there is hypotension, hypovolaemia, hypothermia or liver disease this citrate is rapidly metabolised by the Kreb's cycle. The importance of depressed ionised calcium in shock is still argued and has again become a subject of intense interest. From thepractical point of view, most well-per fused patients are able to tolerate a unit of blood each five minutes without requiring calcium. Common practice dictates that one gram of lO% calcium glutonate should be administered following each five units of whole blood or fresh frozen plasma. Ideally, calcium therapy should be monitored by measuring the ionised calcium levels, a measurement not readily available in many hospitals. ECG monitoring during resuscitation may be helpful. Many workers would suggest that calcium only be given if there are clinical signs of cardiovascular depression in conjunction with ECG changes. Jaundice
Hyperbilirubinaemia is a frequent accompaniment of massive blood transfusion for which there may be several possible explanations (Table 8) . 46 In the context of massive blood transfusion it should be emphasised that a significant amount of transfused blood (up to 30%) may not survive. This results in a large bilirubin load from the breakdown of non-viable transfused red cells. When the patient has been well resuscitated and there is normal liver function, this hyperbilirubinaemia will be unconjugated as classically seen in haemolysis. In contrast, if the patient is hypovolaemic and shocked, liver function may be impaired to varying degrees. The rate-limiting step in bilirubin metabolism is an energy-requiring process for the transportation of conjugated bilirubin from the hepatocyte to the biliary canaliculus. Thus, although an increased load of bilirubin may be rapidly conjugated there may be a delay in its excretion and a conjugated hyperbilirubinaemia may result. This paradoxical cholestatic picture may be misinterpreted and inappropriately investigated. 
Pulmonary oedema
The development of pulmonary oedema is a common complication in the shocked patient. In most patients the clinical picture is that of adult respiratory distress syndrome (ARDS) with several possible mechanisms by which blood transfusion can be implicated, including microaggregates, anaphylaxis, leukoagglutinins, DIC and effects of vasoactive proteins on the pulmonary capillary endothelial membrane. 27 
Mononucleosis syndromes
The development of a swinging pyrexia with or without associated atypical mononucleosis 7-lO days following transfusion can be a source of great diagnostic confusion, leading to numerous investigations and potentially hazardous invasive procedures or even surgery to identify a site of infection. 47 The temperature may fluctuate markedly with associated rigors and sweats, but the patient may feel reasonably well between febrile attacks. Occult sepsis is frequently suspected. It is important that clinicians be aware of this syndrome which is most commonly caused by cytomegalovirus (CMV), but Ebstein-Barr virus, Toxoplasma gondii or unidentifiable agents may be responsible. CMV infection is more severe in splenectomised patients. Differentiation from post-transfusion hepatitis may sometimes be difficult, as liver function abnormalities commonly occur in the mononucleosis syndromes.
The mononucleosis syndromes mainly follow the use of fresh blood products and may be associated with the majority of blood components, including frozen plasma. The syndrome can usually be suspected when the triad of pyrexia, atypical mononucleosis and abnormal liver function occurs 7-lO days after blood component therapy. The blood film should be specifically examined with this syndrome in mind, as the atypical mononuclear cells may have been missed on the initial "routine" examination. The main importance of this syndrome is its recognition, as it has a good prognosis and, except in the immunocompromised host, usually settles down over 2-3 weeks. The offending agent is frequently not identified and there is a tendency to feel the diagnosis has not been confirmed.
